Background: Excessive norepinephrine (NE) release in the ischemic heart elicits severe and often lethal arrhythmias. Resident cardiac mast cells synthesize and store active renin, which is released upon degranulation, causing the activation of a local cardiac renin-angiotensin system (RAS) responsible for NE release and consequent arrhythmias. Toxic aldehydes, known to be formed by lipid peroxidation in ischemia/reperfusion (I/R), have been shown to degranulate mast cells and activate a local RAS.
Objective: To provide an up-to-date description of the roles of ischemic preconditioning (IPC) and Gicoupled receptors in anti-RAS cardioprotection.
Methods: Ex-vivo I/R models in cavian and murine hearts, and human and murine mast cell lines in vitro.
Results: IPC not only drastically reduces the injury subsequent to a prolonged ischemic event, but also decreases mast cell renin release, thus affording anti-RAS cardioprotection. Similarly, activation of Gicoupled receptors, such as histamine-H4, adenosine-A3 and sphingosine-1-phosphate-S1P1 receptors, all expressed at the mast cell surface, mimic the cardioprotective anti-RAS effects of IPC. The mechanism of this action depends on the sequential activation of a specific isoform of protein kinase C, PKCε, and mitochondrial aldehyde dehydrogenase-type 2 (ALDH2). Increased ALDH2 enzymatic activity exerts a pivotal role in the sequential inhibition of aldehyde-induced mast-cell renin release, prevention of RAS activation, reduction of NE release and alleviation of reperfusion arrhythmias.
Conclusion: These recently discovered protective pathways indicate that activation of mast-cell Gicoupled receptors and subsequent ALDH2 phosphorylation/activation represent a novel therapeutic target for the alleviation of RAS-induced cardiac dysfunctions, including ischemic heart disease and congestive heart failure.
Keywords: Aldehyde Dehydrogenase type 2, Gi-coupled proteins, Ischemia/Reperfusion, Ischemic Preconditioning, Mast cells, Norepinephrine.
Acute Coronary Syndromes in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Targeting Cardiomyocyte Ca<sup>2+</sup> Homeostasis in Heart Failure
Current Pharmaceutical Design Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Serum Uric Acid and Risk of Coronary Heart Disease
Current Pharmaceutical Design The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire
Current Medicinal Chemistry Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Current Pharmaceutical Design A Novel Design of Combining the Angiotensin Converting Enzyme (ACE) Inhibitor Captopril with the Angiotensin Receptor Blocker (ARB) Losartan Using Homo Coupling via PEG Diacid Linker
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Endoplasmic Reticulum Stress-induced Transcriptional Factor CHOP and Cardiovascular Diseases
Current Hypertension Reviews Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Hypertension and Counter-Hypertension Mechanisms in Giraffes
Cardiovascular & Hematological Disorders-Drug Targets NADPH Oxidases in the Heart
Current Cardiology Reviews Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery (Discontinued)